

GENEREX BIOTECHNOLOGY CORP

Form 8-K

March 28, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **Monday, 25 March 2019**

Generex biotechnology corpORATION

(Exact of registrant as specified in its charter)

DELAWARE

000-29169

98-0178636

State or other jurisdiction of incorporation Commission File Number IRS Employer Identification No.

10102 USA Today Way, Miramar, Florida 33025

(Address of principal executive offices) (Zip Code)

(416) 364-2551

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Edgar Filing: GENEREX BIOTECHNOLOGY CORP - Form 8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act.

Item 4.02, *Non-Reliance on Previously Issued Financial Statements*

It has been discovered that the 10-Q filed on 25 March 2019 may contain material misstatements concerning the quarterly period ending on 31 January 2019, and should no longer be relied upon. The auditors had not completed their interim review and their comments were not incorporated into the documents as filed. . The Company will be issuing a 10-Q/A correcting any material misstatements, if any, as soon as practicable.

Date: Wednesday, 27 March 2019

/s/ Joe Moscato

By: Joe Moscato, CEO

